For many biotechnology companies, commercialization still feels like something that happens after Phase 3.
First demonstrate that the drug works. Then pursue approval. Then build the commercial organization.
That sequence sounds logical.
But some of the decisions that ultimately determine commercial success are made years earlier—when the clinical-development program is being designed.
By the time a company begins traditional launch planning, many of those decisions may be difficult or impossible to change.
The better question is:
What does this clinical-development decision mean for the product we will eventually have to commercialize?
Phase 3 Is More Than a Regulatory Investment
A pivotal trial can represent one of the largest capital commitments a biotechnology company will make.
The immediate objective is regulatory: generate the evidence required for approval.
But the same trial may also determine the future label, eligible patient population, competitive differentiation, physician confidence and evidence available to payers.
That makes Phase 3 a commercial investment as well as a clinical one.
Before committing that capital, a company should understand not only whether the trial can succeed, but what commercially viable product a successful trial is likely to produce.
Start With the Product You Want at Approval
Consider the decisions made before a pivotal study begins.
Which patients should be enrolled?
How severe should their disease be?
What previous treatments should they have received?
Which endpoints should be measured?
How long should patients be followed?
What outcomes might demonstrate meaningful differentiation from existing or emerging competitors?
Each decision helps define the future product.
If those questions are considered only from the perspective of regulatory approval, the company can reach the end of development with positive data but an uncertain commercial position.
A successful trial is valuable.
A successful trial that also demonstrates why physicians should use the product is considerably more valuable.
The Competitive Market Will Change
Another problem with waiting to consider commercialization is time.
The competitive landscape at the beginning of Phase 3 may not be the landscape at launch.
Programs currently in Phase 1 or Phase 2 may become approved competitors. Treatment guidelines may change. Generic products may become available. New mechanisms may alter physician expectations. Payers may impose different requirements.
Clinical-development strategy therefore needs to look forward.
The relevant question is not simply:
How does our therapy compare with today’s standard of care?
It is:
What will physicians, patients and payers be comparing it with when we reach the market?
That distinction can change which evidence is worth generating today.
Identify the Patient Who Creates the Value
Average clinical results can obscure commercially important differences among patients.
A drug may provide a modest average benefit across the study population while producing a much greater benefit in a particular group.
If that group can be identified, it may become central to the product’s future positioning.
The differentiating characteristic could involve disease severity, treatment history, age, clinical phenotype, biomarker status or another recognizable feature.
The important question is whether the development program is designed to find it.
Who benefits most, and can that patient be identified in clinical practice?
That question should be asked before the pivotal program is locked—not after the data are analyzed.
Payer Evidence Cannot Be an Afterthought
Regulatory approval and reimbursement answer different questions.
Regulators determine whether a therapy is sufficiently safe and effective for approval.
Payers must decide which patients they will pay to treat, under what conditions and where the therapy should sit relative to existing alternatives.
Those decisions may depend on evidence that is not captured adequately by the primary regulatory endpoint.
Treatment burden, hospitalizations, caregiver impact, functional improvement, durability, monitoring requirements and avoidance of other therapies can all influence value.
Health economics and outcomes research therefore should not begin when the commercial team starts preparing for launch.
The evidence a company will eventually need for reimbursement should influence development while there is still an opportunity to generate it.
Capital Should Follow Commercial Evidence
Clinical-stage biotechnology companies operate with limited capital.
Every additional trial, indication and development program competes for those resources.
That makes commercial assessment particularly important before major investment decisions.
A scientifically compelling indication may have a small reachable population.
A larger epidemiological opportunity may require enormous investment in diagnosis and patient identification.
A promising therapy may enter a market where inexpensive established treatments create substantial reimbursement barriers.
Another indication may offer clearer differentiation, concentrated specialists and a more efficient path to patients.
These differences should influence capital allocation.
The objective is not simply to advance the largest number of programs.
It is to invest in the programs capable of creating the greatest sustainable value.
Work Backward Before Moving Forward
Before Phase 3, biotechnology leaders should be able to answer several questions:
- Who will ultimately receive this therapy?
- Why will a physician choose it?
- What will distinguish it from the treatments available at launch?
- What evidence will payers require?
- How many patients can realistically be reached and treated?
- What commercial infrastructure will be required?
- What capital will be needed to reach that point?
The answers will never be perfect. Drug development always involves uncertainty.
But asking these questions before the largest investments are made can expose assumptions while there is still time to change them.
Clinical development and commercialization should not be two separate strategies conducted years apart.
They are different parts of the same investment decision.
About PharmaKonsult
PharmaKonsult advises biotechnology leaders on the clinical-development and commercialization decisions that shape an asset’s future commercial value. Learn more about our biotech commercialization consulting services.
